Introduction: We evaluated knowledge, attitudes, and practices (KAP) related to influenza and influenza vaccination among pregnant women in three selected countries. Methods: During 2017, pregnant women seeking antenatal care at hospitals at participating sites were enrolled. We described characteristics and responses to KAP questions. We also evaluated predictors associated with influenza vaccination during pregnancy at sites with substantial influenza vaccine uptake by multivariable logistic regression. Results: Overall, 4,648 pregnant women completed the survey. There were substantial differences among the three survey populations; only 8% of the women in Nagpur had heard of influenza, compared to 90% in Lima and 96% in Bangkok (p-value<0.01). Despite significant differences in sociodemographic characteristics in the three populations, most participants across sites who were aware of influenza prior to study enrollment believe they and their infants are at risk of influenza and related complications and believe influenza vaccination is safe and effective. Half of women in Lima had verified receipt of influenza vaccine compared to <5% in Bangkok and Nagpur (p < .05). For further analysis conducted among women in Lima only, household income above the poverty line (aOR: 1.38; 95%CI: 1.01, 1.88), having 8+ antenatal visits, compared to 0–4 (aOR: 2.41; 95%CI: 1.39, 2.87, respectively), having 0 children, compared to 2+ (aOR: 1.96; 95%CIs: 1.23, 3.12), and vaccination recommended by a health-care provider (aOR: 8.25; 95%CI: 6.11, 11.14) were strongly associated with receipt of influenza vaccine during pregnancy. Conclusions: Our findings identify opportunities for targeted interventions to improve influenza vaccine uptake among pregnant women in these settings.
21 November 2024 in International Journal of Infectious Diseases
Norovirus is associated with 18% of acute gastroenteritis (AGE) cases worldwide. We aim to document the norovirus-related AGE incidence in peri-urban areas of Lima (Peru), evaluating the potential impact of a norovirus vaccine introduction. A prospective, community-based pediatric cohort study was established at two sites in Lima. Healthy children between 5 and 18 months were contacted weekly for AGE detection during a 6-month period. Stool samples from AGE cases were tested for norovirus by RT-PCR. Incidence and coinfection of norovirus-associated AGE were analyzed. All norovirus-positive samples were genotyped by Sanger DNA sequencing. Among 498 enrolled children, 461 (93%) completed the follow-up period. We detected 799 AGE cases, yielding 676 valid stool samples. Norovirus was detected in 216 samples (32%), with an incidence of 7.7 episodes per 100 child-months (95% CI: 6.7-8.8). Genotypes GII.4 (31%) and GII.6 (22%) were frequent. Campylobacter (43%) and Salmonella spp. (15%) were the most common coinfections with norovirus. Ninety-five percent of study children had received an oral rotavirus vaccine. Norovirus was the second most frequent cause of AGE in this Peruvian cohort with high rotavirus vaccine coverage. An effective norovirus vaccine would have an important public health benefit in this population.
While costs of norovirus acute gastroenteritis (AGE) to healthcare systems have been estimated, out-of-pocket and indirect costs incurred by households are not well documented in community settings, particularly in developing countries. We conducted active surveillance for AGE in two communities in Peru: Puerto Maldonado (October 2012–August 2015) and San Jeronimo (April 2015–April 2019). Norovirus AGE events with PCR-positive stool specimens were included. Data collected in follow-up interviews included event-related medical resource utilization, associated out-of-pocket costs, and indirect costs. There were 330 norovirus-associated AGE events among 3,438 participants from 685 households. Approximately 49% of norovirus events occurred among children <5 years of age and total cost to the household per episode was highest in this age group. Norovirus events cost a median of US $2.95 (IQR $1.04–7.85) in out-of-pocket costs and $12.58 (IQR $6.39–25.16) in indirect costs. Medication expenses accounted for 53% of out-of-pocket costs, and productivity losses accounted for 59% of the total financial burden on households. The frequency and associated costs of norovirus events to households in Peruvian communities support the need for prevention strategies including vaccines. Norovirus interventions targeting children <5 years of age and their households may have the greatest economic benefit.
10 February 2025 in The Journal of Infectious Diseases
Norovirus is the worldwide leading cause of gastroenteric diseases. It affects mainly infants and older adults, but the findings are mainly derived from outbreak investigations rather than population-based cohorts. The U. S. Naval Medical Research Unit SOUTH (NAMRU SOUTH) developed and conducted research studies in the last 20 years focusing on the military and general populations afflicted by this pathogen. For the latter, studies included all age groups in 2 main communities in Peru, representing people from the highlands and tropical areas. The results helped elucidate the incidence of norovirus infection among different age groups as well as identifying risk factors, seasonality, and economic burden on the patient. The collected data demonstrate an increase of norovirus cases, not only in the previously reported age groups but also in adults. Consequently, this increase of norovirus cases in adults may impair the occupational productivity in civilian populations and operational readiness among service members.
10 February 2025 in The Journal of Infectious Diseases
Vaccinating healthcare personnel (HCP) is a top priority for public health globally. This strategy aims not only to protect HCP but also patients, reducing transmission of infections in healthcare services. However, improving vaccine coverage in HCP is still a challenge, especially because they are a risk group for acquiring influenza. Multicomponent influenza vaccination programs targeting behavioral, organizational, and administrative barriers are critical to ensure this priority population is vaccinated. Here, we describe a healthcare worker cohort study that was implemented in Peru, a middle-income country, in 2016, prior to the coronavirus disease 2019 pandemic. This cohort, which is still ongoing, has collected valuable information on influenza vaccine effectiveness, vaccine coverage, risk factors, absenteeism, and use of personal protective equipment, as well as risk of influenza disease, among others. These data can help improve knowledge not only about influenza diseases but also regarding vaccination on this specific influenza risk group in order to improve vaccine uptake.
Background Inborn errors of immunity (IEIs) include more than 500 genetic disorders that cause recurrent infections, autoimmunity, and inflammatory complications. Although classified as rare diseases, their prevalence is increasing, making IEI an emerging public health problem. However, reliable national epidemiological data and coordinated follow-up data of IEI patients are lacking, which potentially affects up to 20,000 people in Peru. Objective In this study, we aim to describe the protocol of a three-phase mixed-method study that will design, build, and evaluate the usability and feasibility of the first Peruvian National IEI Registry. Methods Guided by the Exploration-Preparation-Implementation-Sustainment (EPIS) framework, Phase I (qualitative) will map stakeholder needs through in-depth interviews and focus groups; the data will undergo hybrid thematic analysis in ATLAS.ti. Phase II (pre-experimental) will enroll ≥20 clinical immunology consultants and residents to complete standardized tasks on the REDCap-based prototype; efficiency (task time), effectiveness (error rate), and satisfaction will be compared pre/post-iteration. Phase III (observational) will assess feasibility by enrolling ≥126 IEI cases across six national reference hospitals; the primary outcomes are clinical profile, data completeness, and accuracy. Results The study protocol received institutional review board approval in February 2025 from the UNMSM-Research Ethics Committee. Phase I enrollment started in March 2025. We expect our REDCap-based prototype to incorporate key needs and preferences gathered from focus groups and interviews to develop the platform. By the completion of the study phase II, we will have assessed the usability of the prototype platform. Study phase III will begin in April 2026. The final results are expected by November 2026 and will be published thereafter. Conclusions By evaluating usability and feasibility in real-world conditions, this protocol lays the groundwork for a national IEI registry. The resulting evidence will inform scale-up decisions and facilitate its incorporation into Peruvian health policy. Contributions to the literature - Shows how the EPIS framework can steer real-world adoption of a REDCap-based registry and prospectively measure usability and feasibility across six public hospitals involved in rare-disease surveillance. - Provides a mixed-methods protocol that designs, iterates and field-tests Peru’s first national registry for inborn errors of immunity, tackling persistent barriers to rare-disease data capture in low- and middle-income countries and offering a scalable blueprint for other resource-constrained settings. - Outlines a FAIR-aligned governance and data-sharing strategy that can be adapted by future programmes planning registries for rare and orphan diseases in similar contexts.